ATE393780T1 - Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin - Google Patents

Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin

Info

Publication number
ATE393780T1
ATE393780T1 AT02754557T AT02754557T ATE393780T1 AT E393780 T1 ATE393780 T1 AT E393780T1 AT 02754557 T AT02754557 T AT 02754557T AT 02754557 T AT02754557 T AT 02754557T AT E393780 T1 ATE393780 T1 AT E393780T1
Authority
AT
Austria
Prior art keywords
globulin
medicine
scale production
purification process
product
Prior art date
Application number
AT02754557T
Other languages
German (de)
English (en)
Inventor
Charlotte Svaerke Jorgensen
Inga Laursen
Gunnar Houen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Application granted granted Critical
Publication of ATE393780T1 publication Critical patent/ATE393780T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
AT02754557T 2001-08-14 2002-08-12 Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin ATE393780T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101217 2001-08-14

Publications (1)

Publication Number Publication Date
ATE393780T1 true ATE393780T1 (de) 2008-05-15

Family

ID=8160667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02754557T ATE393780T1 (de) 2001-08-14 2002-08-12 Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin

Country Status (9)

Country Link
EP (1) EP1419177B1 (enExample)
JP (1) JP2005508892A (enExample)
AT (1) ATE393780T1 (enExample)
AU (1) AU2002321012B2 (enExample)
CA (1) CA2456843A1 (enExample)
DE (1) DE60226327T2 (enExample)
DK (1) DK1419177T3 (enExample)
ES (1) ES2305272T3 (enExample)
WO (1) WO2003016348A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778301A2 (en) * 2004-06-29 2007-05-02 Reliance Life Sciences Pvt., Ltd. Process for improvement of virus-safe biological fluids
CN100354301C (zh) * 2005-10-13 2007-12-12 南京工业大学 化学合成多肽的新型大规模分离制备技术
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
SG10201503899SA (en) * 2010-05-18 2015-06-29 Abbvie Inc Apparatus And Process Of Purification Of Proteins
JP5860401B2 (ja) 2010-09-03 2016-02-16 森田薬品工業株式会社 新規Ｇｃグロブリンガラクトース脱糖体の製造方法
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
PL3081221T3 (pl) 2013-12-13 2021-12-27 Saisei Pharma Co., Ltd. Kompozycja farmaceutyczna zawierająca produkt obróbki enzymatycznej siary bydlęcej
CN111632167B (zh) * 2014-04-15 2021-12-28 勃林格殷格翰国际公司 在制造生物制品期间连续灭活病毒的方法、装置和系统
PL3290043T3 (pl) * 2015-06-01 2023-07-03 Saisei Pharma Co., Ltd. Produkt mleczny poddany obróbce enzymatycznej, sposób jego wytwarzania, kompozycja i produkt

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177002A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
ES2124702T3 (es) * 1990-04-11 1999-02-16 Brigham & Womens Hospital Usos terapeuticos de compuestos que se unen a actina.
US6268478B1 (en) * 1996-02-12 2001-07-31 Cedars-Sinai Medical Center Intracellular vitamin D binding protein

Also Published As

Publication number Publication date
WO2003016348A3 (en) 2004-03-04
ES2305272T3 (es) 2008-11-01
DE60226327T2 (de) 2009-07-09
EP1419177B1 (en) 2008-04-30
EP1419177A2 (en) 2004-05-19
DE60226327D1 (de) 2008-06-12
DK1419177T3 (da) 2008-08-25
JP2005508892A (ja) 2005-04-07
WO2003016348A2 (en) 2003-02-27
CA2456843A1 (en) 2003-02-27
AU2002321012B2 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
US10005823B2 (en) Peptides having effects on promoting wound healing, collagen production, angiogenesis, activation of immunocytes and applications thereof
Ma et al. Exercise therapy augments the ischemia-induced proangiogenic state and results in sustained improvement after stroke
NO905264D0 (no) Fremgangsmaate for fremstilling av biologisk aktivt protein
DE60226327D1 (de) Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
ATE121424T1 (de) Hpth-fragment-(1-37), seine herstellung, dieses enthaltende arzneimittel und seine verwendung.
YU73301A (sh) eNOS MUTACIJE,NJIHOVA UPOTREBA ZA PRIPREMU LEKA ZA GENSKU TERAPIJU I POSTUPCI TERAPEUTSKOG SKRININGA
Chen et al. Adjustable parameters and the effectiveness of adjunct robot-assisted gait training in individuals with chronic stroke
Mao et al. Effect of yak milk casein hydrolysate on Th1/Th2 cytokines production by murine spleen lymphocytes in vitro
DE3914869C1 (enExample)
SG72665A1 (en) Method and composition for determining the immunological activity of bioactive substances
Zhang et al. Electroacupuncture promotes nerve regeneration and functional recovery in rats with spinal cord contusion through the coordinate interaction of CD4 and BDNF
DE3585416D1 (de) Verfahren zur herstellung eines biologischen stoffes.
WO2001064240A3 (en) Methods for promoting production of myelin by schwann cells
Arfors et al. Variations in the serum esterases of humans, apes and monkeys
CN104560925A (zh) 一种从人凝血因子ⅸ层析废液中激活制备人凝血酶的方法
CN103789291A (zh) 一种重组大肠杆菌发酵液中分离纯化重组人尿激酶原的制备工艺
HRP20140247T1 (hr) Cjepivo protiv raka
Bekavac et al. Music as medicine
RU2489172C1 (ru) Способ проведения лечебного дискретного плазмафереза с экстракарпоральной модификацией эритроцитов и лейкоцитов индукторами интерферона, антиоксидантами и протекторами клеток
PH22020050168U3 (en) Process for isolating and producing antibodies for the prevention and treatment of covid-19 and related diseases from blood plasma containing said antibodies
Jeon et al. Investigating effects of negative emotional states on the korean elderly's osteoarthritis prevalence
Salami et al. The effect of two Iranian viper snake; vipera albicornuta (zanjani) and vipera latifi i (lattifi i) venoms on the viability of rat bone marrow mesenchymal stem cells in vitro and in vivo
Hockley et al. Biological standards. measuring the potency of biological medicines.
PH22020050169Y1 (en) Intravenous pharmaceutical form of isolated and purified antibodies for the prevention and treatment of covid-19 and related diseases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties